A retrospective, observational, single-centre study of adalimumab in patients with ulcerative colitis (UC) who did not respond to calcineurin inhibitors
Latest Information Update: 02 May 2019
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 02 May 2019 New trial record